Global Biopharmaceutical R&D and Investment Trends
Looking at the recent global drug R&D trends, the growth rate of companies' R&D spending is expected to slow down due to a drop in R&D investment efficiency. Investment efficiency has been decreasing since 2000, and it is analyzed that this is due to governments' policy of lowering drug prices, increasing development costs and periods, and intensifying competition. Biopharmaceutical R&D Trend The pharmaceutical industry is a technology, capital, and device-intensive industry that takes high R&D costs and more than a decade from R&D to successful new drug development and product commercialization. According to a recent report, the cost of marketing a new drug jumped from $1.19 billion in 2010 to $2.17 billion in 2018. 12 Big Bio Companies 12 Big BiosPharmaceutical companies' R&D returns fell to a nine-year low from 10.1% in 2010 to 1.9% in 201, and the cost of launching new drugs has increased to a record level, but the maximum sal...